Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab Variable Dosing in nAMD, RVO, and DME (COVERT)
NCT03056092Phase 4Unknown
- Sponsor
- Unity Health Toronto
- Start
- Feb 2017
- Primary completion
- Feb 2024
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), macular edema, diabetic macular edema (DME), sponsored by Unity Health Toronto. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)macular edemadiabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03056092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03056092.